Epstein Barr Virus (EBV) - Long COVID | drbeen
Get free trial
with access to all our lectures
DrBeen Logo

no credit card required

My Notes

Become a member to create study notes.
Sign up for free trial
Epstein Barr Virus (EBV) - Long COVID Duration: 37:38
Microbiology / Virology
Flashcards Video notes

Learning Objectives

In this lecture Dr. Mobeen will discuss:

1. Epstein Barr virus (EBV) and Infectious mononucleosis. (2:49)

2. Symptoms of EBV infection. (9:05)

3. Pathophysiology of EBV. (14:15)

4. Replication and latency of virus. (20:04)

5. Role of infected B cells in activating cytotoxic T cells. (30:36)

6. Diagnosis of EBV. (34:00)

7. Differential diagnosis of EBV. (35:23)

Instructor

Dr. Mobeen Syed

Dr. Mobeen Syed

Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.


Videos in this series

Epstein Barr Virus (EBV) - Long COVID Epstein Barr Virus (EBV) - Long COVID
Epstein Barr Virus (EBV) Serology Epstein Barr Virus (EBV) Serology
Epstein Barr Virus Prevalence in Long COVID Epstein Barr Virus Prevalence in Long COVID
Epstein Barr Virus Reactivation in COVID Epstein Barr Virus Reactivation in COVID
Absolute Risk Reduction vs Relative Risk Reduction Absolute Risk Reduction vs Relative Risk Reduction
Introduction To P Values and Power Introduction To P Values and Power
COVID-19 Causes Long-Term Blood Cell Changes COVID-19 Causes Long-Term Blood Cell Changes
Early COVID Has Signs For Severe and Long Haul Outcomes Early COVID Has Signs For Severe and Long Haul Outcomes
COVID-19 Primarily A Vascular Disease COVID-19 Primarily A Vascular Disease
New Technique To Study COVID Pathology (High Parameter Imaging Mass Cytometry) New Technique To Study COVID Pathology (High Parameter Imaging Mass Cytometry)
COVID Long Haulers - Mast Cell Activation Syndrome (MCAS) Part - 1 COVID Long Haulers - Mast Cell Activation Syndrome (MCAS) Part - 1
COVID Long Haulers - Mast Cell Activation Syndrome (MCAS) - Part 2 (Symptoms and Management) COVID Long Haulers - Mast Cell Activation Syndrome (MCAS) - Part 2 (Symptoms and Management)
Brain Fog and Other Symptoms In Long Haulers Brain Fog and Other Symptoms In Long Haulers
Defeat Brain Fog With New Neurons - A Review of Neurogenesis Defeat Brain Fog With New Neurons - A Review of Neurogenesis
COVID-19 and Sickle Cell, Thalassemia, and Hemophilia (Full Session) COVID-19 and Sickle Cell, Thalassemia, and Hemophilia (Full Session)
Natural Killer (NK) Cells Natural Killer (NK) Cells
CDC Study - Who Is At Risk of Severe COVID-19 CDC Study - Who Is At Risk of Severe COVID-19
Brain Fog and Other Symptoms In Long Haulers Brain Fog and Other Symptoms In Long Haulers
Preprint Study: Spike Protein Accumulates in The Brain Preprint Study: Spike Protein Accumulates in The Brain
Less Long COVID with Omicron Compared to Its Ancestors Less Long COVID with Omicron Compared to Its Ancestors
Labs to Verify Neurological Toxicity in Long COVID Labs to Verify Neurological Toxicity in Long COVID
Elevated Interleukin 6 (IL-6) and Normal C Reactive Protein (CRP) Elevated Interleukin 6 (IL-6) and Normal C Reactive Protein (CRP)
Two Cases of Multiple Sclerosis After mRNA Vaccine Two Cases of Multiple Sclerosis After mRNA Vaccine
MTHFR Enzyme Deficiency and Cardiovascular Health MTHFR Enzyme Deficiency and Cardiovascular Health
Long COVID Improvement after Therapeutic Apheresis Long COVID Improvement after Therapeutic Apheresis
Evidence for Aerosol Transfer of SARS-CoV-2–Specific Humoral Immunity Evidence for Aerosol Transfer of SARS-CoV-2–Specific Humoral Immunity
FDA Finds Safety Signal after mRNA Vaccine In Children 2-5 Years of Age FDA Finds Safety Signal after mRNA Vaccine In Children 2-5 Years of Age